NRAS mutations had an overall incidence of 3.4% (3/87) in HER2-amplified CRC, occurring at comparable, low rates in HER2-amplified colon cancer (3.3%, 2/61) and rectal cancer (3.8%, 1/26). Here, ERBB2 is linked to malignant colon neoplasm.